AbbVie predicted sharply higher earnings for the new year, driven by rheumatoid-arthritis drug Humira and the launch of its new hepatitis C virus treatment.
via WSJ.com: US Business http://ift.tt/1BNhalz
via WSJ.com: US Business http://ift.tt/1BNhalz
Nessun commento:
Posta un commento